vs
Amphastar Pharmaceuticals, Inc.（AMPH）とGERMAN AMERICAN BANCORP, INC.（GABC）の財務データ比較。上の社名をクリックして会社を切り替えられます
Amphastar Pharmaceuticals, Inc.の直近四半期売上が大きい（$183.1M vs $126.7M、GERMAN AMERICAN BANCORP, INC.の約1.4倍）。GERMAN AMERICAN BANCORP, INC.の純利益率が高く（28.2% vs 13.3%、差は14.8%）。GERMAN AMERICAN BANCORP, INC.の前年同期比売上増加率が高い（39.7% vs -1.8%）。GERMAN AMERICAN BANCORP, INC.の直近四半期フリーキャッシュフローが多い（$154.0M vs $24.6M）。過去8四半期でGERMAN AMERICAN BANCORP, INC.の売上複合成長率が高い（22.7% vs 3.2%）
Amphastar Pharmaceuticalsは上場されている米国の特殊製薬企業です。2004年5月に設立され、主に吸入剤および鼻腔内投与製品の開発、生産、販売を行っており、特色ある医薬品分野で事業を展開しています。
ジャーマン・アメリカン・バンコープ（証券コード：GABC）は米国の銀行持株会社で、多国籍金融サービス企業としてペイメントカード事業を中心に事業を展開しています。本社はニューヨークマンハッタン南部のバッテリーパークシティに位置し、金融分野で豊富な実績を持っています。
AMPH vs GABC — 直接比較
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $183.1M | $126.7M |
| 純利益 | $24.4M | $35.7M |
| 粗利率 | 46.8% | — |
| 営業利益率 | 19.4% | 34.6% |
| 純利益率 | 13.3% | 28.2% |
| 売上前年比 | -1.8% | 39.7% |
| 純利益前年比 | -35.7% | 53.7% |
| EPS（希薄化後） | $0.51 | $0.98 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $183.1M | $126.7M | ||
| Q3 25 | $191.8M | $126.5M | ||
| Q2 25 | $174.4M | $123.2M | ||
| Q1 25 | $170.5M | $111.1M | ||
| Q4 24 | $186.5M | $90.7M | ||
| Q3 24 | $191.2M | $88.5M | ||
| Q2 24 | $182.4M | $90.5M | ||
| Q1 24 | $171.8M | $84.1M |
| Q4 25 | $24.4M | $35.7M | ||
| Q3 25 | $17.4M | $35.1M | ||
| Q2 25 | $31.0M | $31.4M | ||
| Q1 25 | $25.3M | $10.5M | ||
| Q4 24 | $38.0M | $23.2M | ||
| Q3 24 | $40.4M | $21.0M | ||
| Q2 24 | $37.9M | $20.5M | ||
| Q1 24 | $43.2M | $19.0M |
| Q4 25 | 46.8% | — | ||
| Q3 25 | 51.4% | — | ||
| Q2 25 | 49.6% | — | ||
| Q1 25 | 50.0% | — | ||
| Q4 24 | 46.5% | — | ||
| Q3 24 | 53.3% | — | ||
| Q2 24 | 52.2% | — | ||
| Q1 24 | 52.4% | — |
| Q4 25 | 19.4% | 34.6% | ||
| Q3 25 | 13.2% | 34.6% | ||
| Q2 25 | 24.2% | 31.8% | ||
| Q1 25 | 21.9% | 12.0% | ||
| Q4 24 | 24.2% | 31.6% | ||
| Q3 24 | 29.8% | 29.0% | ||
| Q2 24 | 30.3% | 29.4% | ||
| Q1 24 | 27.9% | 27.6% |
| Q4 25 | 13.3% | 28.2% | ||
| Q3 25 | 9.0% | 27.7% | ||
| Q2 25 | 17.8% | 25.5% | ||
| Q1 25 | 14.8% | 9.5% | ||
| Q4 24 | 20.4% | 25.6% | ||
| Q3 24 | 21.1% | 23.8% | ||
| Q2 24 | 20.8% | 22.7% | ||
| Q1 24 | 25.1% | 22.6% |
| Q4 25 | $0.51 | $0.98 | ||
| Q3 25 | $0.37 | $0.94 | ||
| Q2 25 | $0.64 | $0.84 | ||
| Q1 25 | $0.51 | $0.30 | ||
| Q4 24 | $0.74 | $0.79 | ||
| Q3 24 | $0.78 | $0.71 | ||
| Q2 24 | $0.73 | $0.69 | ||
| Q1 24 | $0.81 | $0.64 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $282.8M | — |
| 総負債低いほど良い | $608.7M | $100.0M |
| 株主資本純資産 | $788.8M | $1.2B |
| 総資産 | $1.6B | $8.4B |
| 負債/資本比率低いほどレバレッジが低い | 0.77× | 0.09× |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $282.8M | — | ||
| Q3 25 | $276.2M | — | ||
| Q2 25 | $231.8M | — | ||
| Q1 25 | $236.9M | — | ||
| Q4 24 | $221.6M | — | ||
| Q3 24 | $250.5M | — | ||
| Q2 24 | $217.8M | — | ||
| Q1 24 | $289.6M | — |
| Q4 25 | $608.7M | $100.0M | ||
| Q3 25 | $608.6M | — | ||
| Q2 25 | $607.7M | — | ||
| Q1 25 | $603.9M | — | ||
| Q4 24 | $601.6M | $114.6M | ||
| Q3 24 | $596.4M | — | ||
| Q2 24 | $586.9M | — | ||
| Q1 24 | $594.0M | — |
| Q4 25 | $788.8M | $1.2B | ||
| Q3 25 | $776.7M | $1.1B | ||
| Q2 25 | $757.5M | $1.1B | ||
| Q1 25 | $751.3M | $1.0B | ||
| Q4 24 | $732.3M | $715.1M | ||
| Q3 24 | $727.7M | $744.6M | ||
| Q2 24 | $713.3M | $687.8M | ||
| Q1 24 | $672.4M | $655.3M |
| Q4 25 | $1.6B | $8.4B | ||
| Q3 25 | $1.7B | $8.4B | ||
| Q2 25 | $1.6B | $8.3B | ||
| Q1 25 | $1.6B | $8.4B | ||
| Q4 24 | $1.6B | $6.3B | ||
| Q3 24 | $1.5B | $6.3B | ||
| Q2 24 | $1.5B | $6.2B | ||
| Q1 24 | $1.6B | $6.1B |
| Q4 25 | 0.77× | 0.09× | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | 0.80× | — | ||
| Q4 24 | 0.82× | 0.16× | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | 0.82× | — | ||
| Q1 24 | 0.88× | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $32.9M | $159.3M |
| フリーキャッシュフロー営業CF - 設備投資 | $24.6M | $154.0M |
| FCFマージンFCF / 売上 | 13.4% | 121.6% |
| 設備投資強度設備投資 / 売上 | 4.5% | 4.2% |
| キャッシュ転換率営業CF / 純利益 | 1.35× | 4.46× |
| 直近12ヶ月FCF直近4四半期 | $121.2M | $267.0M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $32.9M | $159.3M | ||
| Q3 25 | $52.6M | $51.8M | ||
| Q2 25 | $35.6M | $26.9M | ||
| Q1 25 | $35.1M | $37.9M | ||
| Q4 24 | $29.0M | $95.8M | ||
| Q3 24 | $60.0M | $24.5M | ||
| Q2 24 | $69.1M | $18.7M | ||
| Q1 24 | $55.3M | $23.9M |
| Q4 25 | $24.6M | $154.0M | ||
| Q3 25 | $47.2M | $50.1M | ||
| Q2 25 | $25.0M | $26.2M | ||
| Q1 25 | $24.4M | $36.7M | ||
| Q4 24 | $16.6M | $90.7M | ||
| Q3 24 | $46.2M | $23.0M | ||
| Q2 24 | $63.1M | $17.0M | ||
| Q1 24 | $46.5M | $22.6M |
| Q4 25 | 13.4% | 121.6% | ||
| Q3 25 | 24.6% | 39.6% | ||
| Q2 25 | 14.3% | 21.2% | ||
| Q1 25 | 14.3% | 33.0% | ||
| Q4 24 | 8.9% | 100.1% | ||
| Q3 24 | 24.1% | 26.0% | ||
| Q2 24 | 34.6% | 18.8% | ||
| Q1 24 | 27.1% | 26.9% |
| Q4 25 | 4.5% | 4.2% | ||
| Q3 25 | 2.8% | 1.3% | ||
| Q2 25 | 6.1% | 0.6% | ||
| Q1 25 | 6.3% | 1.1% | ||
| Q4 24 | 6.7% | 5.6% | ||
| Q3 24 | 7.2% | 1.7% | ||
| Q2 24 | 3.3% | 1.8% | ||
| Q1 24 | 5.1% | 1.5% |
| Q4 25 | 1.35× | 4.46× | ||
| Q3 25 | 3.03× | 1.48× | ||
| Q2 25 | 1.15× | 0.86× | ||
| Q1 25 | 1.39× | 3.61× | ||
| Q4 24 | 0.76× | 4.13× | ||
| Q3 24 | 1.48× | 1.16× | ||
| Q2 24 | 1.82× | 0.91× | ||
| Q1 24 | 1.28× | 1.25× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
GABC
セグメントデータなし
